Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest by Eshaghi, A et al.
Arman Eshaghi, MD
Viktor Wottschel, PhD
Rosa Cortese, MD
Massimiliano Calabrese,
MD
Mohammad Ali Sahraian,
MD
Alan J. Thompson,
FMedSci
Daniel C. Alexander, PhD
Olga Ciccarelli, FRCP
Correspondence to
Dr. Eshaghi:
arman.eshaghi.14@ucl.ac.uk
Supplemental data
at Neurology.org
Gray matter MRI differentiates
neuromyelitis optica from multiple
sclerosis using random forest
ABSTRACT
Objective:We tested whether brain gray matter (GM) imaging measures can differentiate between
multiple sclerosis (MS) and neuromyelitis optica (NMO) using random-forest classification.
Methods: Ninety participants (25 patients with MS, 30 patients with NMO, and 35 healthy con-
trols [HCs]) were studied in Tehran, Iran, and 54 (24 patients with MS, 20 patients with NMO, and
10 HCs) in Padua, Italy. Participants underwent brain T1 and T2/fluid-attenuated inversion recov-
ery MRI. Volume, thickness, and surface of 50 cortical GM regions and volumes of the deep GM
nuclei were calculated and used to construct 3 random-forest models to classify patients as
either NMO or MS, and separate each patient group from HCs. Clinical diagnosis was the gold
standard against which the accuracy was calculated.
Results: The classifier distinguished patients with MS, who showed greater atrophy especially in
deep GM, from those with NMO with an average accuracy of 74% (sensitivity/specificity: 77/72;
p , 0.01). When we used thalamic volume (the most discriminating GM measure) together with
the white matter lesion volume, the accuracy of the classification of MS vs NMO was 80%. The
classifications of MS vs HCs and NMO vs HCs achieved higher accuracies (92% and 88%).
Conclusions: GM imaging biomarkers, automatically obtained from clinical scans, can be used to
distinguish NMO from MS, even in a 2-center setting, and may facilitate the differential diagnosis
in clinical practice.
Classification of evidence: This study provides Class II evidence that GM imaging biomarkers can
distinguish patients with NMO from those with MS. Neurology® 2016;87:1–8
GLOSSARY
AQP4-Ab 5 aquaporin-4 autoantibody; EDSS 5 Expanded Disability Status Scale; FLAIR 5 fluid-attenuated inversion
recovery; GM 5 gray matter; HC 5 healthy control; LPBA 5 LONI Probabilistic Brain Atlas; MS 5 multiple sclerosis;
NMO 5 neuromyelitis optica; NMOSD 5 neuromyelitis optica spectrum disorder.
Neuromyelitis optica (NMO) shares similar clinical and imaging characteristics with multiple
sclerosis (MS), but a correct and timely diagnosis is essential for managing patients as treatment
options differ considerably. Differential imaging characteristics include more pronounced brain
atrophy, especially in the cortical gray matter (GM), in patients with MS than in patients with
NMO 1; more severe thalamic changes in MS than NMO2,3; and a lack of cortical lesions in
NMO.1,4,5
Machine-learning algorithms have shown promise in classifying MRI scans of patients with
neurologic disorders.6 Their advantage over human observers is that they can handle a large
number of variables from each patient and lack inconsistencies. Hence, they offer potential in
the clinical setting to support the diagnostic process, and have been used successfully in Alz-
heimer disease,7 traumatic brain injury,8 and clinically isolated syndromes suggestive of MS.9
Random-forest classification is a powerful machine-learning approach for classification prob-
lems, such as distinguishing patients with different diseases, or separating neurologic patients
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from healthy controls (HCs), on the basis of
their MRI scans, especially in multicenter
studies.7 A random forest is a set of decision
trees trained to answer a decision problem, for
example: To which of the 2 groups does
a patient belong? It starts with a training phase
to construct a set of trees, each using a random
subset of the training data, to characterize dif-
ferences between groups. The testing (or vali-
dation) phase then predicts to which of the
groups new cases belong by combining votes
from the set of decision trees.10
We tested whether GM measures, obtained
from MRI scans acquired as part of clinical
protocols, can distinguish MS from NMO.
In particular, we calculated the thickness, vol-
ume, and surface area of the cortex, and the
volume of the basal ganglia, which reflect the
underlying GM pathology.11 To test whether
this can be used in a multicenter setting, we
used data from 2 different centers. Finally, we
investigated the GM measures that contrib-
uted most to the discrimination of MS from
NMO, in order to obtain insights into the
underlying pathology of these diseases.
METHODS Our primary question was whether imaging bio-
markers extracted from routine MRI measures discriminate
between MS and NMO. The case-control design of this work
provides Class II evidence.
Participants. In this retrospective study, we collected all data from
consecutive patients with relapsing-remitting MS and NMO. They
were recruited in 2 tertiary centers, one in Iran (January 2009–
December 2012)12 and one in Italy (June 2013–December 2013).
The diagnosis of MS was made according to the McDonald criteria,
which were revised in 2005,13 and that of NMO according the
Wingerchuk criteria, which were revised in 2006.14 This study
started and was completed before the publication of the new NMO
criteria, but a retrospective evaluation showed that all patients with
NMO fulfilled the 2015 criteria for NMO spectrum disorder
(NMOSD).15 Other inclusion criteria were the absence of (1)
concomitant neurologic or psychiatric disorders and (2) clinical
relapses or IV methylprednisolone administration at least 6 weeks
prior to the study entry.
Standard protocol approvals, registrations, and patient
consents. All participants gave written informed consent16
and for each cohort the local ethics committee approved the
project.
Clinical assessment and MRI protocol. All patients were clin-
ically examined and the Expanded Disability Status Scale (EDSS) was
scored on the day ofMRI scan.17 All participants underwentMRI scans
that included high-resolution 3DT1 and T2 fluid-attenuated inversion
recovery (FLAIR) imaging, at 1.5T in Padua and 3T in Tehran. The
MRI protocol for each cohort is shown in table e-1 at Neurology.org.
Image analysis. We analyzed the scans of both centers in the
same way. The aim was to calculate cortical volume, thickness,
and surface area in 25 cortical regions for each hemisphere
defined by LONI Probabilistic Brain Atlas (LPBA),18 and the
volumes of deep GM nuclei (the accumbens, amygdala, cau-
date, pallidum, putamen, and thalamus). We performed image
analysis in ANTs software (v1.9) and FSL (v5.0) (fsl.fmrib.ox.
ac.uk/fsl/).
We manually constructed binary lesion maps on FLAIR/T2
scans, coregistered them with the T1 scan, and used this to fill hypo-
intense lesions of T1 scans to avoid segmentation errors in patients.19
Next, we constructed a study-specific template as a common space
for registration.20 We calculated transformation matrices from the
atlas space to the common template, and then to each participant’s
native space, and applied it to LPBA labels to transfer them into
native space to extract the imaging measures.
To calculate the cortical thickness, we used a new
registration-based approach that has recently been validated.21,22
We calculated the surface area, at each cortical region, by dividing
cortical volume by the thickness. We used FSL FIRST to calcu-
late volumes of the deep GM structures.23
Classification analysis. We performed all statistical analysis in
R version 3.1.0 and Scientific Python 2.7 libraries (Scikit-Learn
package).24,25 We calculated 157 variables, which were the cortical
thickness, surface area, and volume of each cortical region, and
the volume of each deep GM nucleus. We divided regional vol-
umes by the total intracranial volume to adjust for different head
sizes.26 We adjusted each GM measure separately for the effect of
age. We fitted a linear regression line where age was the indepen-
dent variable and each GM measure was the dependent variable.
We calculated the amount of the GM measure that remained
unexplained by the regression model (residual of the fit) and used
it for all the subsequent analyses.
To investigate the effect of different centers and MRI scan-
ners on the classification, we added the variable “center” to the
analysis. Next, we constructed 3 models to differentiate between
each pair of groups: (1) MS vs NMO; (2) MS vs HCs; and (3)
NMO vs HCs. For each model, we randomly assigned partici-
pants from both centers to either the training or test set, so that
each set contained half of the participants. Next, we performed
the training step, and then the cross-validation on the left-out half
(with 5,000 repetitions). The mean and SD of the accuracy of
5,000 trained and cross-validated models were calculated. Clinical
diagnosis of MS or NMOwas the gold standard against which the
classification accuracy was calculated.
We used default values of random forest parameters as pro-
vided by the Scikit learn package, and calculated the importance
of variables according to the original random-forest algorithm.10
Moreover, when distinguishing between MS and NMO, we built
models using cortical region volume, thickness, surface area, and
deep GM nuclei volumes, first on their own, and then in com-
bination, to assess the effect of each measure on the accuracy,
using a cross-validation approach as explained above. Since a ran-
dom subset of variables is chosen for each decision tree in a forest
of decision trees, random-forest classifiers are not affected by
collinearity (correlation among surface, thickness, and volume).10
In a post hoc analysis, we simplified the model to assess the
accuracy in distinguishing NMO fromMS by including the most
discriminating GM variable and white matter lesion load. Finally,
we trained the NMO vs MS classifier with the scans of patients
with NMO who were AQP4-positive and tested it to distinguish
the scans of patients with NMO who were AQP4-negative from
those with MS.
To gain a better understanding of GM changes, boxplots of
the median and 75th percentile of cortical thickness, surface area,
and volumes of the subcortical regions were calculated.
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RESULTS Participants.We included 144 participants;
90 participants (25 patients with MS, 30 patients with
NMO, and 35 HCs) were recruited in Tehran, Iran,12
and 54 (24 patients with MS, 20 patients with NMO,
and 10 HCs) in Padua, Italy. The clinical and demo-
graphic characteristics are shown in table 1 (for treat-
ment information, see table e-2).
Seventeen out of 30 patients diagnosed with
NMO from the Tehran cohort tested positive for
aquaporin-4 autoantibody (AQP4-Ab) (immunofluo-
rescence method, bioscientia.de/en/), while 18 out of
20 patients from the Padua cohort were AQP4-Ab
positive (cell-based assay, euroimmun.com). Patients
in the Italian cohort had significantly higher disability
than those studied in Iran (MS: median EDSS 4.0 vs
2.5, p , 0.05; NMO: 4.5 vs 3, p , 0.05, respec-
tively). Disease duration was not significantly differ-
ent between the 2 cohorts. There was a significant
difference in age between groups (table 1).
Classification results. The average accuracy of the
model for NMO vs MS trained with all GM imaging
features was 74%, with a sensitivity of 77% (i.e., 77%
of patients with MS were classified as MS) and a spec-
ificity of 72% (i.e., 72% of patients without MS, but
with NMO, were classified correctly) (p, 0.01 calcu-
lated against a classifier with randomly changed, or
permuted, labels and corrected for multiple compari-
sons with Bonferroni method) (table 2 and figure e-1).
When cortical volume, cortical thickness, and surface
area were used on their own to classify the 2 groups of
patients, the average accuracy was lower (59%, 62%,
and 66%, respectively) (figure 1). The results of the
analysis remained the same when not adjusting for age.
A high accuracy (92%) was obtained when distin-
guishing MS from HCs (sensitivity/specificity 94/90;
p , 0.001); the accuracy of classifying NMO vs
HCs was also high (88%; sensitivity/specificity 89/
88; p , 0.001).
Variable importance. The volumes of the deep GM
structures were the most important GM measures
to distinguish MS from NMO, while the volumes
of cortical regions were more important in distin-
guishing patients from HCs. In general, the GM vol-
umes were more useful to the classification than the
cortical thickness and surface area.
MS vs NMO. The volumes of the deep GM (the
thalami, right pallidum, and putamina) followed by
the insular thickness, which showed reduction in
MS compared to NMO (figures 1 and 2), were the
most important GM measures to distinguish MS
from NMO.
When looking at individual effects of GM meas-
ures (cortical and subcortical volumes, surface area,
and thickness) to distinguish between NMO and
MS, the combination of all measures gave the best
accuracy, which was similar to the accuracy of the
classification obtained using only the deep GM vol-
umes (figure 1D), but higher than that obtained
using each measure on its own.
When we used the thalamic volume (the most dis-
criminating GM measure) together with the white
matter lesion volume (see figure e-2), the average
accuracy of the classification of MS vs NMO (over
5,000 permutations) was 80% (sensitivity/specificity
85%/76%, p , 0.001).
When we trained the NMO vs MS classifier using
the data from people with NMO who were AQP4-
positive and tested on people with NMO who were
AQP4-negative, the performance of the model was
similar to that of the model that trained and tested ran-
domly selected scans from all people with NMO regard-
less of serostatus (average 6 SD accuracy 77% 6 12,
sensitivity 74%6 19, specificity 80% 6 15).
NMO vs HC. The volumes of the parahippocampal
gyri and the left middle frontal gyrus were the most
important variables for this classification; these regions
showed smaller volumes in patients with NMO as com-
pared to HCs (figure 2).
MS vs HC. The volumes of the bilateral parahippo-
campal gyri and the right superior temporal gyrus were
the most important variables for this classification
Table 1 Demographic characteristics of participants from each country
Tehran cohort Padua cohort Both cohorts
p ValueaHC MS NMO HC MS NMO HC MS NMO
No. 35 25 30 10 24 20 45 49 50
Age, y, mean 6 SD 32 6 9.1 32.85 6 8.5 33.58 6 10.1 36.04 6 8.4 36 6 7.9 42.47 6 7 33 6 8.9 34.4 6 8.3 37 6 10 0.04
Disease duration, y,
mean 6 SD
— 7 6 5.5 6.1 6 3.3 — 8.1 6 3.2 7.47 6 2.2 — 7.5 6 4.4 6.5 6 3 NS
Median EDSS (range) — 2.5 (1–5.5) 3 (1–6) — 4 (2.5–7) 4.5 (0–7.5) — 3 (1–7) 3.5 (0–7.5) NS
Female:male 31:4 22:3 26:4 9:1 12:12 11:9 40:5 34:15 37:13 NS
Abbreviations: EDSS 5 Expanded Disability Status Scale; HC 5 healthy controls; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica; NS 5 nonsignificant.
ap Values are for analysis of variance for age, t test for disease duration, and EDSS, and x2 test for sex.
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(these regions showed reduced volumes in MS when
compared to HCs). The variable “center” (i.e., Tehran
and Padua) was consistently found to be the least
important feature for all the classifications.
DISCUSSION Previous imaging studies have high-
lighted differences in MRI characteristics between
NMO and MS1,12,27,28, but an automatic distinction is
still challenging. Here, we automatically classified pa-
tients with MS and NMO on the basis of their brain
MRI scans routinely acquired with clinical protocols,
using a random-forest classifier. Our findings showed
that GM imaging measures, such as cortical thickness,
cortical surface area, and subcortical GM volumes, led to
an accuracy of 74% when classifying the 2 patient
groups, which is higher than that obtained with each
GM measure on its own. When we used both the most
discriminating GM measure (the thalamic volume) and
the white matter lesion volume, the accuracy of the
model in classifying NMO vs MS was higher (80%)
than the original model. Random-forest classification
accuracy was higher for distinguishing MS from HCs
(92%) and NMO from HCs (88%), because the
classification task is less challenging than discriminating
the 2 diseases. Therefore, this automatic approach may
support the diagnostic process in clinical practice, for
example in patients with NMOSD without AQP4.
The variable “center” did not significantly affect the
classification. Moreover, the contribution of imaging
features to the classification was more relevant than the
differences in clinical characteristics, which may exist
between patient cohorts.
We demonstrated that the volumes of the deep
GM, which were lower in people with MS than
NMO (figure 2A), were more important features
for discriminating NMO and MS than cortical thick-
ness and volume. Our results are in line with a recent
study that failed to show significant thalamic atrophy
in NMO when compared to HCs,2,3 while another
study detected a mild reduction in thalamic volume
in NMO when compared to HCs.1 The thalamic
volume loss in MS may be related to secondary neuro-
degeneration occurring in cortical areas or may rep-
resent primary neurodegeneration,1,2,11 whereas in
NMO a milder neurodegeneration secondary to axo-
nal degeneration in spinal cord or visual pathways is
present.29
Cortical thickness represents the number of neu-
rons in each cortical column.30 The thickness of the
insular cortices had the second highest discriminating
value (after the deep GM volumes) in distinguishing
MS from NMO. This region shows a predilection for
atrophy, especially as patients with MS progress.31
The insula is deep in the temporal lobe and may be
more exposed to inflammatory mediators than other
cortical areas.31
While atrophy in regions such as the thalamus
and insula was only seen in MS, both demyelinating
diseases seemed to affect the parahippocampal gyrus
in a similar fashion (figure 2). The parahippocam-
pus is part of the limbic system and has extensive
connections to temporal, frontal, and deep GM re-
gions. Transection of these connections, which oc-
curs as a result of white matter lesions, could lead to
atrophy of this region via retrograde neurodegener-
ation in both diseases.32,33 In addition, in MS, GM
damage might be the result of either noninflamma-
tory or inflammatory processes that have occurred
within the GM itself.32,34 In NMO, the GM loss is
more selective and depends on AQP4 expression,
and the ratio of M1 to M23 proteins in astrocytes.33
The parahippocampus may show a different pattern
of AQP4 expression or may be connected to areas
with high AQP4 expression, although the dynamic
pattern of AQP4 expression in the brain remains
unclear.35,36
Table 2 Classification results
Variables
Accuracy,
average 6 SD
Sensitivity,
average 6 SD
Specificity,
average 6 SD
Positive predictive
value, average 6 SD
Negative predictive
value, average 6 SD p Valuea
All gray matter
measures
MS vs NMO 74% 6 5 77% 6 11 72% 6 10 73% 6 8 76% 6 9 ,0.01
MS vs HCs 92% 6 4 94% 6 6 90% 6 7 91% 6 6 93% 6 7 ,0.001
NMO vs HCs 88% 6 5 89% 6 8 88% 6 8 89% 6 6 87% 6 8 ,0.001
Thalamic volume and white
matter lesion volume
MS vs NMO 80% 6 5 85% 6 9 76% 6 9 78% 6 6 84% 6 8 ,0.001
Abbreviations: HC 5 healthy controls; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica.
Accuracy was defined as the percentage of patients correctly identified by the classifier as either MS or NMO. Sensitivity was defined as the number of
participants correctly identified by the classifier (MS or NMO) divided by all participants diagnosed with each disease. Specificity is defined as the number
of participants correctly labeled as not having the disease divided by all participants without the disease.
aCorrected for multiple comparisons with Bonferroni method.
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Patients with NMO may have severe relapses affect-
ing the motor or visual system.37 However, GM meas-
ures of the occipital or motor cortices did not distinguish
between NMO and MS or HCs. These findings are
consistent with previous voxel-based morphometry stud-
ies in NMO that failed to show detectable changes in the
GM volume of these regions when compared to MS or
HCs.2,38,39 Another study found mild thinning of the
calcarine, precentral, and postcentral cortices in NMO
when compared to HCs, but no significant differences
between NMO and MS.1
One strength of our study is that we included partic-
ipants from 2 centers. We previously demonstrated, in
a 1-center setting using scans from the same Iranian pa-
tients used in this study, that a combination of
advanced MRI modalities (functional MRI and diffu-
sion tensor imaging) distinguishes between MS and
NMOwith high accuracy, using a technique called data
Figure 1 Importance of variables in the classifiers differentiating multiple sclerosis (MS), neuromyelitis optica (NMO), and healthy controls
(HCs)
(A–C) The importance of each variable to classification inside random-forest algorithm. Importance is a relative measure, and is normalized to sum to 1 for
eachmodel, and should be used to compare the importance of variables inside eachmodel (not amongmodels). (D) The accuracy of models with different gray
matter measures, including cortical volumes, cortical surface area, cortical thickness, thickness and surface area in combination, and subcortical volumes.
The combination of surface area and thickness obtains a higher accuracy than volume. Each model has been trained and tested 1,000 times, after shuffling
participants from 2 centers. DGM 5 deep gray matter.
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fusion with multikernel learning.12 The limitations of
this technique are that it is computationally intensive
and its application in multicenter studies is limited. The
present work, using a random-forest classification, is
more robust in a multicenter setting, and is less likely
to overfit.10 We included center as a variable in our
analysis and found that it had the lowest importance
in all 3 classifications: NMO vs MS, MS vs HC, and
NMO vs HC. We repeated the cross-validation 5,000
times, which allowed the inclusion of all patients in
Figure 2 Descriptive statistics of the thickness, surface, and volume of deep gray matter (DGM) nuclei and cortical regions
(A) DGM nuclei. (B) Cortical regions. Left and right hemisphere values are averaged for better visualization. All measures have been normalized, and the Z
scores were calculated. HC 5 healthy control; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica.
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both training and test sets. This could be generalized to
other centers, provided that sufficient participants from
new centers are included in the training sample. More-
over, for an easier application we simplified the model
including only thalamic volume and white matter lesion
volume; this achieved 80% accuracy in distinguishing
between MS and NMO. In the future, greater accuracy
may be achieved by including additional features, such
as lumbar puncture results, antibody status and quan-
titative spinal cord measures.40,41
In this study, patients with NMO were signifi-
cantly older than patients with MS, and therefore
we adjusted GM measures for age. NMO has a later
disease onset thanMS,37 so after we matched 2 groups
according to disease duration, age was higher in
NMO than MS. However, despite older age, which
has the effect of reducing GM volume,42 patients with
NMO had higher GM volume than those with MS,
which suggests that age is unlikely to be a confounder
in our analysis. Moreover, we have built our model
using scans of patients with a secure diagnosis of MS
or NMO, with a mean disease duration of 7.5 years.
This is because the clinical diagnosis of MS or NMO
was the gold standard against which the classification
accuracy was calculated. An important question to be
addressed in future studies is whether this algorithm
can help to classify difficult radiologic cases or to pre-
dict the outcome after the first attack. For example, in
a previous study we found that machine learning cor-
rectly predicted the presence (or absence) of clinically
definite MS in 71.4% of patients within 1 year of
onset of a clinically isolated syndrome.9
This study is not without limitations. First, the
NMO group, which was recruited prior to the revised
criteria for the diagnosis of NMOSD,15 included both
AQP4-negative and AQP4-positive patients (15 nega-
tive and 50 positive). Recent work has highlighted the
possible different clinical and radiologic characteristics
between these 2 groups that may indicate distinct sub-
types.43 There were no notable differences in age, sex,
or clinical disability between NMO without AQP4
(2 from Italy, 13 from Iran) and NMO with AQP4.
However, the group of seronegative patients was small.
In the future, this technique could help to identify
patients with NMOSD without AQP4, since in this
cohort they show similarities with the NMOSD with
AQP4 cases; in particular, the algorithm correctly clas-
sified them in 77% of NMOSD without AQP4 cases
after having learned from only the NMOSD with
AQP4 cases. Second, the role of GM lesions in distin-
guishing between the 2 diseases was not assessed,1
because the sequences that allow GM lesion detection
are not routinely acquired in the clinical setting. Fur-
ther studies will clarify these issues.
We showed that the random-forest classification
robustly and automatically discriminates between MS
and NMO on the basis of MRI scans in a 2-center set-
ting with up to 80% accuracy. Furthermore, deep GM
volumes and cortical thickness of specific key regions
may give increased power to detect subtle GM features,
which may facilitate the differential diagnosis between
MS and NMO.
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